HC Wainwright Has Pessimistic Outlook of ETON Q1 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Stock analysts at HC Wainwright decreased their Q1 2026 EPS estimates for shares of Eton Pharmaceuticals in a note issued to investors on Monday, March 2nd. HC Wainwright analyst S. Ramakanth now expects that the company will earn $0.20 per share for the quarter, down from their prior forecast of $0.23. HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ FY2027 earnings at $1.95 EPS and FY2030 earnings at $4.42 EPS.

ETON has been the subject of a number of other reports. Zacks Research upgraded Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Wall Street Zen downgraded Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $31.00.

Eton Pharmaceuticals Price Performance

NASDAQ:ETON opened at $17.45 on Wednesday. Eton Pharmaceuticals has a 52-week low of $11.09 and a 52-week high of $23.00. The company has a market cap of $468.01 million, a P/E ratio of -69.80 and a beta of 1.19. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.25 and a current ratio of 1.63. The stock’s 50-day simple moving average is $16.22 and its 200 day simple moving average is $17.24.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ETON. Caitong International Asset Management Co. Ltd bought a new stake in Eton Pharmaceuticals in the 4th quarter valued at $50,000. Invesco Ltd. increased its holdings in shares of Eton Pharmaceuticals by 46.1% in the fourth quarter. Invesco Ltd. now owns 19,691 shares of the company’s stock valued at $333,000 after purchasing an additional 6,213 shares during the last quarter. XTX Topco Ltd raised its position in shares of Eton Pharmaceuticals by 33.3% in the fourth quarter. XTX Topco Ltd now owns 32,527 shares of the company’s stock valued at $550,000 after purchasing an additional 8,128 shares during the period. Millennium Management LLC raised its position in shares of Eton Pharmaceuticals by 400.1% in the fourth quarter. Millennium Management LLC now owns 79,331 shares of the company’s stock valued at $1,341,000 after purchasing an additional 63,469 shares during the period. Finally, Jump Financial LLC acquired a new stake in shares of Eton Pharmaceuticals during the 4th quarter worth about $178,000. 27.86% of the stock is currently owned by institutional investors.

Key Headlines Impacting Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: In‑license and upcoming commercial launch of HEMANGEOL®: Eton acquired U.S. commercialization rights to HEMANGEOL (the only FDA‑approved systemic therapy for infantile hemangioma) and will begin U.S. commercialization on May 1, 2026. Management says the deal is expected to be accretive to 2026 earnings and will be supported by Eton’s Eton Cares patient program (including a $0 co‑pay initiative). Read More.
• Positive Sentiment: Analyst upgrades/price target increases: Two boutique research firms raised targets and maintain Buy ratings — HC Wainwright moved its target to $37 and Craig Hallum to $30, both implying large upside versus current levels. Analyst optimism likely supported earlier buying ahead of the launch. Read More.
• Positive Sentiment: Market reaction to the acquisition: Coverage and headlines from MarketWatch and BayStreet reported shares rising on the HEMANGEOL commercialization news, consistent with the accretion story and product leverage to 2026 revenue. Read More.
• Neutral Sentiment: Upcoming earnings date announced: Eton will report Q4 and full‑year 2025 results on March 19, 2026 (conference call at 4:30 p.m. ET). That event can amplify volatility as investors reassess revenue and margin drivers tied to recent product additions. Read More.
• Neutral Sentiment: Short‑interest data appears anomalous: Recent short‑interest entries show zero shares/NaN changes and 0.0 days‑to‑cover — likely a reporting/data issue rather than a market signal. Investors should treat short‑interest readings with caution until corrected. (Internal data entries)
• Negative Sentiment: Safety profile and commercialization execution risks: HEMANGEOL carries serious safety warnings (hypoglycemia, bradycardia, breathing problems, stroke risk in certain patients). Successful commercialization and physician/patient adoption are not guaranteed and could limit uptake or invite additional scrutiny. Read More.
• Negative Sentiment: Profitability and balance‑sheet context: Eton remains unprofitable (negative P/E) and will fund the HEMANGEOL deal from cash on hand; investors should watch upcoming results for margin impact, cash burn, and whether sales trajectories meet the accretion assumptions analysts used in raising targets.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.